Colorectal Cancer
Conditions
Keywords
pMMR/MSS, PCSK9, chemotherapy
Brief summary
The purpose of this study is to preliminarily observe the efficacy and safety of PCSK9 inhibitors in combination with standard advanced first-line regimens in the treatment of advanced colorectal cancer with pMMR/MSS.
Detailed description
The purpose of this study is to preliminarily observe the efficacy and safety of PCSK9 inhibitors in combination with standard advanced first-line regimens in the treatment of advanced colorectal cancer with pMMR/MSS. To evaluate progression-free survival (PFS) after PCSK9 inhibitor combination, overall survival (OS) after PCSK9 inhibitor combination, and to evaluate the safety and tolerability of PCSK9 inhibitor combination therapy based on NCI-CTCAE version 4.03, and to further explore efficacy predictive biomarkers based on changes in the expression of specific immune markers in blood and tissue specimens at baseline and after treatment.
Interventions
DRUGPCSK9 inhibitor in combination with standard advanced first-line regimen group
Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
DRUGstandard advanced first-line regimen group
Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
Sponsors
Guangdong Provincial People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Experimental: Advanced Treatment combined with PCSK9 inhibitor Control: Advanced Treatmentcombined without PCSK9 inhibitor
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years old, gender is not limited, and signed informed consent; 2. Histologically confirmed colorectal adenocarcinoma with pMMR/MSS; 3. Colorectal cancer with distant metastasis or inability to be radically surgically resected as assessed by imaging examination Patient; 4. Immunohistochemistry or sequencing to evaluate the high expression status of PCSK9 in tumors; 5. ECOG score 0-1; 6. Expected survival ≥ 3 months.
Exclusion criteria
1. Hypocholesterolemia, hypolipidemia and its family history, previous allergic reaction to PCSK9 inhibitors History of allergic reaction to PCSK9 inhibitors; 2. preoperative pathological diagnosis of advanced colorectal adenocarcinoma without pMMR/MSS, with the chance of radical surgical treatment; 3. Hypolipidemia caused by combination with other long-term lipid-lowering drugs; 4. malignancies other than colorectal cancer with negligible risk of metastasis or death (e.g., expected 5-year OS \>90%) within 5 years prior to enrollment and for which a radical outcome is expected after treatment (e.g., adequately treated carcinoma in situ of the uterine cervix, basal or squamous cell skin cancers, limited prostate cancers treated for radical purposes, ductal carcinomas in situ treated for radical purposes surgically), with the exception of (b) the following; 5. history of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis; 6. major surgery within 4 weeks prior to enrollment or incomplete recovery from previous surgery; 7. systemic immunostimulatory drug therapy (including but not limited to interferon or IL-2) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to enrollment; 8. pre-existing or clinically significant CNS disease at screening, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndromes, or psychiatric disorders; 9. receipt of systemic corticosteroids (\>10 mg/d prednisone equivalent) or other systemic immunosuppressants, etc. within 2 weeks prior to randomization; 10. previous allogeneic bone marrow transplantation or previous solid organ transplantation; 11. subjects who, in the judgment of the Investigator, have any factors affecting compliance with the protocol, including uncontrollable medical, psychological, familial, sociological, or geographic conditions; or who are unwilling or unable to comply with the procedures required in the study protocol; 12. history of idiopathic pulmonary fibrosis, drug-induced pneumonia, organic pneumonia (i.e., occlusive bronchiolitis), idiopathic pneumonia, or evidence of active pneumonia on CT scan of the chest at the time of screening; 13. receipt of any live vaccine (e.g., vaccines against infectious diseases such as influenza vaccine, varicella vaccine, etc.) within 4 weeks (28 days) prior to randomization 14\. Pregnant or lactating female patients; 15\. Hypersensitivity to fluorouracil-based or platinum-based agents or their excipients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rateObjective response rate (ORR) | 5years | Objective response rate (ORR) after PCSK9 inhibitor in combination with standard advanced first-line regimen in patients with advanced colorectal cancer with pMMR/MSS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 5years | Progression-free survival (PFS) after PCSK9 inhibitor combination therapy |
| Overall survival (OS) | 5years | Overall survival (OS) after PCSK9 inhibitor combination therapy |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety evaluation index | During the study | According to NCI-CTCAE version 4.03, the safety and tolerability of PCSK9 inhibitor combination therapy |
Contacts
Primary ContactYONG LI, Doctor
Outcome results
None listed